Interpol deal with drug firms to fight fake medicines

Interpol on Tuesday announced a deal with the world's top pharmaceutical companies to fight fake drugs which threaten the health of millions, especially in poor countries.

Twenty-nine leading companies have pledged 4.5 million euros ($5.9 million) over three years to improve the fight against the counterfeit industry, boost public awareness and crack down on illegal manufacturers.

"With no country, no drug, no medical product immune from counterfeiting, a global effort is needed to combat this threat which puts the lives of millions of people at risk every single day," said Interpol Secretary General Ronald K. Noble.

Others highlighted the potentially deadly hazards of fake medicines.

"In the case of drug counterfeiting, it can mean the difference between life and death for a patient," said Christopher Viehbacher, the head of French drug firm Sanofi.

"It is estimated that 10 percent of medicines are fake and these figures can go up to 50 percent, particularly in some poorer countries."

According to the more than 50 percent of medicines bought online have been found to be fake.

Counterfeit and other medicines laced with diethylene glycol have caused eight mass around the world including in 2006 in Panama where more than 100 people died, many of them children, an Interpol statement said.

In 2012, some 109 in Pakistan died after taking fake medicine, it added.

add to favorites email to friend print save as pdf

Related Stories

Internet led to global 'explosion' of fake drugs

Jun 14, 2012

The rapid growth of Internet commerce has led to an explosion of counterfeit drugs sold around the world, with China the biggest source of fake medicines, pharmaceutical experts said Thursday.

China breaks up fake medicine racket

Nov 04, 2011

China said Friday it had busted a gang that produced and sold fake medicine -- some made of animal feed -- arresting 114 suspects and seizing more than 65 million counterfeit tablets.

Recommended for you

Added benefit of vedolizumab is not proven

17 hours ago

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments